key: cord-0069408-zjde060p authors: Bigaud, Marc; Rudolph, Bettina; Briard, Emmanuelle; Beerli, Christian; Hofmann, Andreas; Hermes, Erwin; Muellershausen, Florian; Schubart, Anna; Gardin, Anne title: Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights date: 2021-11-03 journal: Mult Scler J Exp Transl Clin DOI: 10.1177/20552173211049168 sha: d6053358ea824c0d5a036f8f9c7cfcd2cd63a074 doc_id: 69408 cord_uid: zjde060p BACKGROUND: Siponimod (BAF312), a selective S1P(1)/S1P(5) agonist, reduces disability progression in secondary progressive MS. Recent observations suggest it could act via S1P(1)/S1P(5)-dependent anti-inflammatory and pro-myelination effects on CNS-resident cells. OBJECTIVE: Generate preclinical evidence confirming siponimod's CNS penetration and activity. METHODS: Siponimod's CNS penetration and distribution was explored in rodents and non-human primates (NHPs) using: Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS), quantitative whole-body autoradiography (QWBA) using (14)C-radiolabeled siponimod or non-invasive single-photon emission CT (SPECT) with a validated (123)I-radiolabeled siponimod analog. Functional CNS activity was investigated by S1P(1) receptor quantification in brain homogenates. RESULTS: In mice/rats, siponimod treatments achieved dose-dependent efficacy and dose-proportional increase in drug blood levels, with mean brain/blood drug-exposure ratio ((Brain/Blood)DER) of 6–7. Efficacy in rat brain tissues was revealed by a dose-dependent reduction in brain S1P(1) levels. QWBA distribution analysis in rats indicated that [(14)C]siponimod related radioactivity could readily penetrate CNS, with particularly high uptakes in white matter of cerebellum, corpus callosum, and medulla oblongata versus lower exposures in other areas such as olfactory bulb. SPECT monitoring in NHPs revealed CNS distribution with a (brain/blood)DER of ∼6, as in rodents. CONCLUSION: Findings demonstrate siponimod's CNS penetration and distribution across species, with high translational potential to human. Siponimod is the first oral disease-modifying therapy shown to reduce disability progression, cognitive decline, total brain volume loss, gray matter atrophy, and signs of demyelination in secondary progressive multiple sclerosis (SPMS) patients. [1] [2] [3] It is a potent and selective agonist for two of the five known membrane G-protein-coupled receptors for sphingosine-1phosphate (S1P)-receptor subtypes 1 and 5 (S1P 1 and S1P 5 ) that has demonstrated robust immunomodulatory, anti-inflammatory, pro-myelination, and neuroprotective properties in various preclinical models. [4] [5] [6] [7] It was recently approved, as Mayzent®, for the treatment of relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease (RRMS), and SPMS, in adults (USA) 8 and for SPMS patients with active disease (Europe). 9 The immunomodulatory properties of siponimod involve S1P 1 -dependent retention of bloodpathogenic lymphocytes within secondary lymphoid organs, as established previously for fingolimod (FTY720, Gilenya®), the prototype S1P-modulator approved as an oral agent for RRMS, 10, 11 and for all the S1P 1 agonists described thus far. 12, 13 The underlying molecular mechanisms involve internalization and degradation (down-modulation or functional antagonism) of S1P 1 receptors on proinflammatory T-and B-lymphocytes. 10 Consequently, lymphocytes become unresponsive to the S1P gradient, depriving them of an obligatory signal to egress from secondary lymphoid organs and thus preventing their recirculation to susceptible target organs such as the central nervous system (CNS). In addition, siponimod's apparent anti-inflammatory, pro-myelination, and neuroprotective properties might be attributable to S1P 1 /S1P 5 -dependent effects on CNS-resident cells, as strongly suggested by numerous preclinical observations. 4, 6, [14] [15] [16] Understanding siponimod's mechanism of action therefore requires exploration of its ability to penetrate and distribute within CNS tissues. A first set of evidence supporting CNS penetration for siponimod was obtained in mice 17 ; and the present study aimed to consolidate these observations by assessing CNS penetration/distribution for siponimod, and siponimod-related radioactive material (siponimod and/or metabolites), in rodents and in a more translational relevant preclinical species such as non-human primates (NHPs). 18, 19 Materials and methods All studies in rodents were performed in accordance with protocols approved by the Cantonal Veterinary Office of Basel and according to regulations defined by the European Community Council Directive for animal protection. Briefly, adult female C57BL/6J mice (18-19 g; Charles River or Harlan Laboratories Switzerland) and male Long Evans or Han:Wistar rats (220-230 g; Janvier, France/Harlan, The Netherlands) were group housed and had free access to tap water and standard diet (Maus/Ratte Haltung GLP, KLIBA NAFAG-3890; Provimi Kliba AG, Switzerland). Housing rooms were temperature controlled (22 ± 2°C) throughout the study period. Animal housing, care, and experimental use were conducted according to the Swiss Federal Law for animal protection. Studies in NHPs were carried out under institutional animal care protocols complying with US-Federal regulations. Animal housing/care approval and oversight was provided by the Rush University, Chicago, Illinois IACUC. Briefly, 2 male rhesus macaques (Macaca mulatta) housed at the Rush University Medical Center in Chicago (Illinois, USA) were used for SPECT imaging. Imaging was conducted under institutional animal care protocols complying with Federal regulations. Studies in mice. These studies aimed at measuring siponimod concentrations in blood and brain in mice treated with siponimod-loaded diet for at least 10 days at various doses. Mice were either healthy or subject to experimental autoimmune encephalomyelitis (EAE): • In healthy mice: C57BL/6 mice were randomization in treatment groups (n = 6/group) and fed for 10 days with siponimod-loaded food pellets (prepared as described in Supplementary These studies aimed at monitoring, in 2 male rhesus macaques, siponimod brain penetration and distribution, via non-invasive singlephoton emission CT (SPECT), using a specific tracer (MS565), a previously validated 123 I-radiolabeled imaging analog for siponimod. 17 Parts of these works were previously reported. 20 Details concerning the SPECT analysis are described in Supplementary Information. All test materials used in different studies were supplied by Novartis, Basel, Switzerland (see Supplementary Information) . The whole blood lymphocyte counts were measured with the use of an ADVIA 120 Hematology System with MultiSpecies Software [BAYER] . Plasma samples were prepared by centrifugation (2000 g for rodent, 3000g for NHP) of blood aliquots at 4°C for 10 min. All blood, plasma, and brain tissue samples were stored at −80°C until further processing for siponimod content via LC-MS/MS or radioactivity measurements. Further technical details concerning analysis of biological samples collected are described in the Supplementary Information. For the EAE study, clinical score comparisons between treatment groups were evaluated on a daily basis and compared to vehicle control. All statistical analyses of clinical score parameters used a Mann-Whitney rank sum test For S1P 1 levels in tissues, a parametric Student's T-test was utilized. All statistical analyses were performed using GraphPad Prism version 6 for Windows, (GraphPad Software, USA). Statistical significance was set at p < 0.05. Siponimod penetrates mouse CNS in a dose-proportional manner and protects against the development of EAE Both heathy and EAE mice fed with siponimodloaded food pellets showed dose-proportional steady-state siponimod levels in blood and brain homogenates, with markedly higher levels in brains for all siponimod doses tested ( Figure 1 ). Similar siponimod levels were determined in the cerebral cortex versus rest of brain, although there was a trend for the levels to always be the lowest in the cortex. In heathy mice, the dose-proportional increase in siponimod blood levels resulted in a dose-dependent reduction in blood lymphocyte counts (Figure 2 (a)), with a maximal reduction of about 80% achieved at a diet-loading dose of 10 mg/kg (approximatively equivalent to a daily drug intake of 30 µg/mouse or 1.5 mg/kg). At this dose, the mean siponimod levels achieved in whole blood and brain homogenates were within the 500 nM and 3 µM ranges, respectively. Higher drug exposures did not induce stronger reduction in blood lymphocytes. For all doses tested, the mean drug-exposure ratio between brain homogenates and blood ( Brain/Blood DER) approached 6, suggesting a steady CNS penetration for siponimod across a wide dose-range. In EAE mice, the dose-proportionality of the siponimod levels in blood and brain homogenates were aligned with those seen in healthy mice. As blood drug levels tended however to be a bit lower than in healthy mice, a mean Brain/Blood DER around 7 was found for all doses tested ( Figure 1 ). In addition, all the siponimod doses tested were efficacious at significantly reducing the blood lymphocyte counts by 70-80% (p < 0.05; details not shown), as well as the development of EAE scores (p < 0.05), with a maximal efficacy obtained at the diet-loading dose of 10 mg/kg ( Figure 2 (b)). At this dose, the mean siponimod levels in whole blood and brain homogenates were within the 400-500 nM and 3-3.5 µM ranges, respectively. Higher drug exposures did not result in significantly stronger protection against EAE. Siponimod penetrates rat CNS and is pharmacologically active The siponimod concentrations in blood, plasma, brain homogenates, and CSF measured 8 h post-last treatment in rats treated for 7 consecutive days with siponimod at 0.01, 0.1, or 1 mg/kg/day (rat study 1) are shown in Figure 3 (a). Siponimod concentrations in blood and plasma were within the same range and increased in a dose dependent manner, reaching the 2-, 12-, and 120-nM range at 0.01, 0.1, and 1 mg/ kg/day, respectively. Nearly 6-fold higher drug levels were measured in brain homogenates (i.e. ∼16, 70 and 700 nM range, respectively), indicating brain/blood (DER) or brain/plasma (DER) around 6, as in mice. In CSF, siponimod concentrations within 0.2 nM were detected only with the highest treatment dose of 1 mg/kg/day, indicating a CSF/brain ratio reaching 0.0003 and therefore suggesting that the siponimod measured in brain tissues was mostly (>99.9%) bound to tissues. The siponimod concentrations achieved in brains were associated with a dose-dependent downmodulation of S1P 1 receptors in brain homogenates, as indicated by measurements of S1P 1 protein levels ( Figure 3(b) ). There was no significant effect for siponimod at 0.01 mg/kg/day (∼16 nM in brain tissues) and average reductions of 36% and 78% in S1P 1 protein levels were observed for siponimod at 0.1 Figure 1 . Dose-proportional steady-state siponimod levels in healthy and EAE mice. Healthy and EAE mice were fed for several days with siponimod-loaded food pellets at various concentrations (0.1 to 200 mg of siponimod per kg of food). Steady-state siponimod concentrations reached in blood and brain homogenates are shown (c, cortex; r, rest of the brain). Dotted lines link results obtained in healthy mice whereas plain lines are used for EAE mice. Blood concentrations are expressed as nM and in brain as pmol/g (equivalent to nM). All points are mean ± SEM (n = 6-10). For each dose tested, the mean Brain/Blood DER was calculated. and 1 mg/kg/day (∼70 and 700 nM in brain tissues), respectively, versus vehicle control. To track siponimod concentrations over time in plasma versus brain and CSF, rats were treated with 3 mg/kg/ day siponimod and samples were collected at 8, 24, 72, and 168 h after the last treatment (rat study 2). The plasma siponimod levels measured at 8 h posttreatment reached a mean concentration range of 0.7 µM, whereas ∼3-fold higher levels were measured in brain (2.3 µM) (Table 1) . Simultaneously, mean siponimod concentrations within the 6 nM range were detected in CSF, i.e. 340-fold lower compared to brain. At 24 h post-last treatment, siponimod concentrations in plasma, brain, and CSF were reduced versus 8 h values by 90%, 50%, and 70%, respectively. At 72 h post-treatment, siponimod could no longer be detected in plasma and CSF but was still measurable in brains (∼35 nM range). Taken together, these results suggest siponimod's dose-proportional CNS penetration and efficacy on S1P 1 receptors in rats, with specific kinetic profiles in plasma, brain tissues and CSF. The markedly lower concentrations of siponimod measured in CSF versus brain tissues suggest that siponimod measured in CNS tissues is mostly (>99.9%) bound to tissues. This is in line with previous studies proposing that drug levels measured in the CSF are surrogate measurements for brain unbound concentrations. 21 Figure 3 . Dose-dependent siponimod levels in rats. Rats were treated orally for 7 days with siponimod at 0.01, 0.1, and 1 mg/kg/day (n = 3/group): (a) Siponimod concentrations in blood, plasma, brain, and CSF, at 8 h after the last treatment. Blood, plasma, and CSF concentrations are expressed in nM and brain levels in pmol/g (equivalent to nM); (b) Mean amount of S1P 1 protein detected in the brain homogenates of the treated rats, as expressed in % versus vehicle-treated group. *p < 0.05, ***p < 0.005. CSF, cerebrospinal fluid; DER, drug-exposure ratio; S1P, sphingosine 1-phosphate; SEM, standard error of the mean. siponimod-related radioactivity measured in various brain regions are shown in Figure 4 (b). The corresponding calculated tissue PK parameters are listed in Table 2 . Following 7 daily oral doses of 3 mg/kg/day [ 14 C] siponimod hemifumarate, the related radioactivity was taken up into the brain extensively with areas under the concentration-time curves from time zero to the last measurable concentration normalized to blood AUC last (AUC last tissue/blood ratios) of 5.0-23.2, suggesting regional differences for the distribution of [ 14 C]siponimod-related radioactivity in the CNS. Highest AUC last tissue/blood ratios were observed for spinal cord (white matter (23.2), the white matter of cerebellum (15.1), corpus callosum (12.9), and medulla oblongata (12.4) . Interestingly, about 2-fold higher siponimod exposures could be observed in white versus gray matters of the brain and spinal cord ( Table 2) . Two rhesus macaques received a single intravenous bolus injection of [ 123 I]MS565 and were monitored over 3 days for brain SPECT imaging. A representative example of the [ 123 I]MS565 SPECT monitoring is shown in Figure 5 (a). Overall, [ 123 I]MS565 displayed good brain penetration, with brain-tissue uptake (particularly marked in cortical and thalamic areas) increasing over 26-32 h post-injection and then slowly washing out up to 48 h. Quantitative analysis of these SPECT images resulted in a more precise kinetic of drug uptake (expressed as standard uptake value (SUV) by brain tissues) ( Figure 5(b) ) and revealed a peak CNS uptake within 18-24 h post-injection. At that time, the [ 123 I]MS565 levels measured in plasma suggest that its elimination from plasma was nearly completed (>90%) and indicate a Brain/Plasma DER of ∼6, as seen in mice and rats. To better analyze the distribution of [ 123 I]MS565 within the different brain regions, SPECT and T1-weighted MRI images obtained over 7-48 h postinjection were merged (Figure 6(a) ). This analysis suggested that a small fraction of [ 123 I]MS565 reached the brain ventricles and that different uptake might exist between white and gray matter. The comparative dynamic uptake of [ 123 I]MS565 for cortical gray matter and white matter is shown in Figure 6 (b), together with a polynomial fit to the data from both animals. Hence, drug uptake (expressed as SUV) increased up to 18-20 h postinjection to reach up to ∼1.6 in gray matter versus 1.8 in white matter (0.011% vs 0.012% injected dose (ID)/mL, respectively), suggesting a 13% preference uptake for white matter. Washout of [ 123 I] MS565 appeared faster in gray versus white matter, with SUV at 48 h post-injection reduced to ∼0.9 in gray matter and ∼1.25 in white matter (0.006% vs 0.008% ID/mL, respectively), suggesting a 39% preference residual uptake for white matter. The aim of the present investigations was to generate preclinical insights concerning the CNS penetration, distribution, and activity of siponimod, thus, elucidating its direct pharmacological effects in the CNS to help explain its therapeutic benefit in SPMS. 3 The first compelling evidence on the central efficacy for S1P 1 agonists, in addition to their inhibitory effects on lymphocyte trafficking, came from a study showing that fingolimod had lost therapeutic efficacy in an EAE model using conditional null mouse mutants lacking S1P 1 receptors on astrocytes but not on lymphocytes. 22 Since then, observations accumulated supporting S1P 1 -dependent effects in the CNS for fingolimod, 23 as well as siponimod. 4, 6, [14] [15] [16] The molecular events downstream of the S1P 1 receptors remain to be fully understood as both S1P 1 down-modulation and activation of signaling pathways involved in the regulation of astrocyte survival and proliferation have been described. 16, 24, 25 Recently, siponimod was shown to induce, in human astroglial cells, an S1P1-dependent activation of the anti-oxidant/ anti-inflammatory/neuroprotective transcription factor Nrf2 in parallel to the blockade of the pro-inflammatory transcription factor NFκB. 26 Less is known about central S1P 5 -dependent effects on oligodendrocytes, although they were shown to be mainly pro-myelinating. 6, 15 Concerning CNS penetration of siponimod, previous preclinical studies in mice suggested that it could be achieved upon a single intravenous bolus application with, at ≤ 8 h post-dosing, a maximal blood exposure associated with a markedly higher (∼5 fold) drug levels in brain tissues. 17 The present study confirms these observations in healthy mice, rats and NHPs, strongly suggesting that the ability of siponimod to dose-dependently penetrate and distribute into the CNS compartment is preserved across species, with a Brain/Blood DER maintained within the range of 5-6, independently of the dose or regimen used. In the mouse, siponimod treatments were applied via drug-loaded diet, as preliminary work indicated that it was a robust alternative to daily oral gavage for achieving efficacious siponimod blood exposures in chronic mouse disease models. 27 The present results clearly confirm that such a treatment can indeed achieve a dose-proportional increase in steady state siponimod blood levels and a dose-dependent pharmacological efficacy (reduction in circulating lymphocytes) with a maximal effect at a food-loading dose of 10 mg/kg. As expected, the same food-loading dose of 10 mg/kg was also found maximally efficacious in reducing the development EAE symptoms, further illustrating the relevance of EAE models as mechanistic tools for studying the anti-inflammatory/immunomodulatory effects of S1P modulators. [10] [11] [12] [13] Interestingly, for all siponimod doses tested in EAE mice, a Brain/Blood DER around 7 was measured, suggesting that the CNS penetration of siponimod is not subject to major changes during the development of the disease. In the rat, a dose-proportional increase in siponimod blood levels could also be achieved via daily oral gavage with, as in mice, a brain/blood (DER) around 6 for all dose tested. Pharmacological efficacy in the CNS could be demonstrated by a dose-dependent reduction in S1P1 levels in brain tissues, in line with previous observations describing drug-induced S1P 1 down-modulation in CNS-resident cells 24, 25, 28 or brain tissues. 29, 30 For technical reasons, no benchmarking with other S1P receptors could be performed and follow up studies are therefore warranted. Available data however suggest that the S1P 3 , S1P 4 and S1P 5 receptors contrast vs S1P 1 upon activation by fingolimod, with partial down-modulation for S1P 3 29 and no down-modulation at all for S1P 4 29,31 and S1P 5. 29,32 Such behaviors of S1P receptors in brain tissues are most likely not affected by the development of central inflammation, as suggested by studies showing that, although the S1P 1 and S1P 3 expressions are increased on astrocytes in MS and EAE lesions, they can be reduced by the administration of fingolimod. 33, 34 Confirmation would certainly be justified with the help of dedicated EAE studies. Concerning the distribution of siponimod throughout the rat CNS, it was assess via QWBA analysis which revealed a specific tissue distribution pattern of [ 14 C] siponimod related radioactivity within the different CNS areas, with highest concentration of siponimod related radioactivity detected for the white matter of the cerebellum, corpus callosum, medulla oblongata and spinal cord, and twice as low levels in the olfactory bulb. These results, suggesting that the distribution of siponimod throughout the CNS is subject to marked regional selectivity, motivated follow up confirmatory studies in NHPs. The clinical relevance of NHPs as a model to predict brain penetration and distribution of drugs in human has been well documented 18, 19 and SPECT imaging in NHPs was previously validated as a translational method to estimate brain penetration of fingolimod. 35, 36 Validation was performed using BZM055, a radiolabeled surrogate for fingolimod that demonstrated similar brain distribution patterns between NHPs and humans. The same approach was therefore followed for evaluating the brain penetration of siponimod in NHPs with [ 123 I]MS565, previously validated as a reliable SPECT tracer for siponimod. 17, 20 SPECT results obtained in the present study indicate good brain penetration for siponimod in NHPs, with high levels versus other tissues surrounding the brain and with particularly high uptake in cortical and thalamic areas, a slight preference for white versus gray matter, and a quite residual appearance in CSF. Taken together the present investigations demonstrate consistent brain penetration/ distribution for siponimod across species, which is suggestive of a high translational potential to human. Although this type of information is key to confirm that siponimod has the intrinsic properties to physically access CNS-resident cells expressing S1P 1 /S1P 5 receptors, it is of semi-qualitative nature and, as such, does not by itself ascertain that local unbound siponimod levels would also reach the concentration range required for biological activity in humans. Additional quantitative imaging studies in humans, with evaluation of receptor occupancy would be an additional helpful next step to provide further evidence to that end. Available pharmacological data, uncorrected for protein binding, indicate a potency for siponimod on S1P 1 /S1P 5 receptors within the 1 nM range 5 and efficacy on cultured astrocytes or oligodendrocytes within the 10-100 nM range. [14] [15] [16] Corrected values for the binding-to-brain tissues, as estimated for siponimod in the present study (>99.9%) and fully in line with >99.9% binding-to-plasma protein in human, 37 might project that unbound siponimod CNS levels within the 0.01-0.1 nM range could be needed for preclinical in vivo efficacy. Such a range was most likely reached in rats treated with siponimod at 3 and 1 mg/kg/day, as indicated by the drug levels measured in the CSF (∼6 and 0.2 nM, respectively), which can be considered as surrogate measurements for brain unbound drug concentrations. 21 Translation to humans is currently unclear as limited siponimod CSF information in human is at present available and would require dedicated studies using clinical imaging technologies. Of the 1651 patients enrolled in the EXPAND trial, 3 only nine (∼0.5%) accepted CSF sampling at end of treatment, five of whom could be confirmed as siponimod treated due to occurrence of siponimod (low nM range) in the CSF. An intriguing observation from the present studies is that the Brain/Blood DER and Brain/Plasma DER for siponimod were found to be ∼6 across the doses and species tested, suggesting persistence along evolution of the underlying mechanisms controlling siponimod's CNS penetration. Despite several investigations, no active transporter for siponimod has been identified as yet (unpublished in house observation), suggesting that its CNS penetration is driven by its high lipophilicity (logD 7.4 = 2.6) 17 and passive membrane diffusion. In this case, the CNS penetration of siponimod is not expected to be markedly affected by the development of local inflammatory conditions, as supported by a Brain/Blood DER of ∼7 found in EAE mice. Although the consistency of Brain/Blood DER and Brain/Plasma DER across doses and species for siponimod suggests a good translation to human, dedicated studies in healthy volunteers vs MS patients, using clinical imaging technologies, would be warranted to provide confirmation. Benchmarking to other S1P modulators would also clarify pharmacokinetic/pharmacodynamic relationships for different molecules from the same pharmacological class and the possible link between CNS penetration and central efficacy. Hence, available comparative data suggest that, although the CNS penetration for both fingolimod and its active phosphorylated metabolite are similar to siponimod in healthy rodents (with Brain/Blood DER ∼6), they increase by at least 3 fold during EAE development, 38, 39 in strong contrast to siponimod. For ozanimod, its CNS penetration is about twice as high vs siponimod and fingolimod in healthy rodents ( CNS/Blood DER of [10] [11] [12] [13] [14] [15] [16] and the impact of EAE has not been described as yet. 40 Too high CNS levels might however be counterproductive for S1P modulators to achieve efficacy in the CNS compartment concomitantly to the periphery as recent observations suggest that S1P receptor-dependent central antiinflammatory, neuroprotective, and/or promyelination effects are subject to a non-classical pharmacology, characterized by a loss of efficacy at supramaximal exposures (bell-shaped doseresponse curves). [41] [42] [43] [44] Overall, these preclinical studies suggest a robust dose-proportional CNS penetration/distribution with central pharmacological efficacy for siponimod, with a high translational potential to human. The proportion between specific and unspecific binding to the CNS tissues remains to be established, as well as the pharmacokinetic profile of siponimod in the CNS versus blood. Follow-up preclinical and clinical studies will be helpful to identify the molecular mechanisms controlling siponimod CNS exposure and to fully understand how siponimod distributes within the CNS, in relation to its well-described pharmacodynamic effects (anti-inflammatory, neuroprotective, pro-myelination) 6,14-16 at the level of CNS-resident cells. Impact of siponimod on myelination as assessed by MTR across SPMS subgroups: post hoc analysis from the EXPAND MRI substudy Siponimod reduces grey matter atrophy in patients with secondary progressive multiple sclerosis: subgroup analyses from the EXPAND study (1130) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate The Xenopus tadpole: an in vivo model to screen drugs favoring remyelination Discovery of BAF312 (siponimod), a potent and selective S1P receptor modulator Mayzent® summary of product characteristic 2020 FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function From natural product to the first oral treatment for multiple sclerosis: the discovery of FTY720 (gilenya)? The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators Sphingosine 1-phosphate receptor agonists promote axonal ensheathment by human fetal oligodendrocyte progenitors Fingolimod modulates microglial activation to augment markers of remyelination The dual S1PR1/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures MS565: a SPECT tracer for evaluating the brain penetration of BAF312 (siponimod) Demystifying brain penetration in central nervous system drug discovery. Miniperspective Prediction of human brain penetration of P-glycoprotein and breast cancer resistance protein substrates using In vitro transporter studies and animal models Brain distribution of MS565, an imaging analogue of siponimod (BAF312) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes Siponimod (BAF312) activates Nrf2 while hampering NFκB in human astrocytes, and protects from astrocyte-induced neurodegeneration Optimising siponimod (BAF312) oral administration for long-term experimental studies in mice Mouse astrocytes exhibit agonist-induced functional S1P1 receptor antagonism Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination Fingolimod treatment is associated with a down-modulation of S1P1 receptor protein in the CNS The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptor The S1P5 receptor is not down-modulated in response to selective agonists Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions Fingolimod may supportnNeuroprotection via blockade of astrocyte nitric oxide An iodinated radiotracer candidate for PET and SPECT imaging of myelin and FTY720 brain distribution Brain distribution of BZM055, an analog of fingolimod (FTY720), in human Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: a single-dose, openlabel, parallel-group study Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis Differentiated pharmacokinetic/pharmacodynamic (PK/PD) profiles for siponimod vs fingolimod Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity Siponimod: from understanding mode of action to differentiation versus fingolimod Dual mode of action of siponimod in secondary progressive multiple sclerosis: a hypothesis based on the relevance of pharmacological properties Sphingosine 1-phosphate receptor subtype 1 as a therapeutic target for brain trauma Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices All authors met the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. All authors are responsible for intellectual content and data accuracy. We are grateful to Esther van de Kerkhof, Adriana Tavarez, Paul Maguire, Olivier Barret, Meike Lang, Lea Baumgartner, Pamela Ramseier, Sarah Tisserand, and Julien Perdoux for their expert technical support. We thank Swetha Sanugomula (Novartis Healthcare, Hyderabad, India) for providing medical writing support, which encompassed formatting of the manuscript content, referencing, tables and figures as per the journal guidelines, and incorporating the authors' revisions and finalizing the draft for submission, all under the direction of the authors. All authors are employees of Novartis and author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article Funding Novartis Pharma AG, Basel, Switzerland funded the study and medical writing support for the preparation of this manuscript. https://orcid.org/0000-0002-1168-5311 Andreas Hofmann https://orcid.org/0000-0001-5450-6267 Supplemental material for this article is available online.